I-Mab Doses First Patient in Phase III Trial of Novel Growth Hormone Therapy

I-Mab, a Shanghai biotech, has dosed the first patient in a pivotal China Phase III trial of a weekly treatment for pediatric growth hormone deficiency (PGHD). Eftansomatropin alfa (TJ101) is an innovative long-acting recombinant human growth hormone (rhGH) with a novel molecular format that includes Genexine's half-life extension hyFc® fusion technology. Most rhGHs have to be injected daily. The primary endpoint is non-inferiority to Norditropin®, the current standard of care. More details.... Stock Symbol: (NSDQ: IMAB) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.